Oro-mucosal drug delivery company, SUDA Pharmaceuticals Limited (ASX:SUD) released its quarterly report for the three-month period ended 31st March 2020. The Company highlighted the following key developments for the March quarter:
- Commencement of Dr Michael Baker’s role as SUDA’s CEO.
- Appointment of General Manager for Perth operations.
- Signing of a new licence pact with MTPK (Mitsubishi Tanabe Pharma Korea Ltd) pertaining to ZolpiMist.
- Kicking off feasibility studies with Ordesa and Sanofi.
The Company’s cash receipts stood at $323,000 for the quarter, with a bank balance of $1,508,000 at 31st March 2020.
As at 12:07 PM AEST on 30th April 2020, SUD is trading at $0.049 with a rise of ~2.1 per cent.